Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 187(2): 225-233, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27669117

RESUMO

Infliximab (IFX) has been used repeatedly in mouse preclinical models with associated claims that anti-inflammatory effects are due to inhibition of mouse tumour necrosis factor (TNF)-α. However, the mechanism of action in mice remains unclear. In this study, the binding specificity of IFX for mouse TNF-α was investigated ex vivo using enzyme-linked immunosorbent assay (ELISA), flow cytometry and Western blot. Infliximab (IFX) did not bind directly to soluble or membrane-bound mouse TNF-α nor did it have any effect on TNF-α-induced nuclear factor kappa B (NF-κB) stimulation in mouse fibroblasts. The efficacy of IFX treatment was then investigated in vivo using a TNF-α-independent Trichuris muris-induced infection model of chronic colitis. Infection provoked severe transmural colonic inflammation by day 35 post-infection. Colonic pathology, macrophage phenotype and cell death were determined. As predicted from the in-vitro data, in-vivo treatment of T. muris-infected mice with IFX had no effect on clinical outcome, nor did it affect macrophage cell phenotype or number. IFX enhanced apoptosis of colonic immune cells significantly, likely to be driven by a direct effect of the humanized antibody itself. We have demonstrated that although IFX does not bind directly to TNF-α, observed anti-inflammatory effects in other mouse models may be through host cell apoptosis. We suggest that more careful consideration of xenogeneic responses should be made when utilizing IFX in preclinical models.


Assuntos
Colite/tratamento farmacológico , Fibroblastos/efeitos dos fármacos , Infliximab/uso terapêutico , Macrófagos/efeitos dos fármacos , Tricuríase/tratamento farmacológico , Trichuris/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Animais , Anticorpos Bloqueadores/uso terapêutico , Apoptose/efeitos dos fármacos , Células Cultivadas , Colite/parasitologia , Epitopos , Fibroblastos/fisiologia , Humanos , Infliximab/farmacologia , Macrófagos/parasitologia , Masculino , Camundongos , Camundongos Endogâmicos AKR , Camundongos Knockout , Ligação Proteica , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/imunologia
2.
Cell Death Differ ; 23(7): 1219-31, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26868913

RESUMO

Interleukin-1ß (IL-1ß) is a critical regulator of the inflammatory response. IL-1ß is not secreted through the conventional ER-Golgi route of protein secretion, and to date its mechanism of release has been unknown. Crucially, its secretion depends upon the processing of a precursor form following the activation of the multimolecular inflammasome complex. Using a novel and reversible pharmacological inhibitor of the IL-1ß release process, in combination with biochemical, biophysical, and real-time single-cell confocal microscopy with macrophage cells expressing Venus-labelled IL-1ß, we have discovered that the secretion of IL-1ß after inflammasome activation requires membrane permeabilisation, and occurs in parallel with the death of the secreting cell. Thus, in macrophages the release of IL-1ß in response to inflammasome activation appears to be a secretory process independent of nonspecific leakage of proteins during cell death. The mechanism of membrane permeabilisation leading to IL-1ß release is distinct from the unconventional secretory mechanism employed by its structural homologues fibroblast growth factor 2 (FGF2) or IL-1α, a process that involves the formation of membrane pores but does not result in cell death. These discoveries reveal key processes at the initiation of an inflammatory response and deliver new insights into the mechanisms of protein release.


Assuntos
Inflamassomos/metabolismo , Interleucina-1beta/metabolismo , Trifosfato de Adenosina/farmacologia , Animais , Caspase 1/metabolismo , Linhagem Celular , Transferência Ressonante de Energia de Fluorescência , Células HEK293 , Humanos , Taninos Hidrolisáveis/farmacologia , Interleucina-1beta/genética , Lipopolissacarídeos/toxicidade , Lipossomos/metabolismo , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos , Microscopia de Fluorescência , Permeabilidade/efeitos dos fármacos , Potássio/análise , Potássio/metabolismo , Precursores de Proteínas/genética , Precursores de Proteínas/metabolismo , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes de Fusão/genética
3.
Integr Biol (Camb) ; 7(6): 713-25, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25990200

RESUMO

Live-cell imaging of fluorescent fusion proteins has transformed our understanding of mammalian cell signalling and function. However, some cellular systems such as immune cells are unsuitable or refractory to many existing transgene delivery methods thus limiting systematic analyses. Here, a flexible lentiviral gene transfer platform for dynamic time-lapse imaging has been developed and validated with single-molecule spectroscopy, mathematical modelling and transcriptomics and used for analysis of a set of inflammation-related signalling networks. Time-lapse imaging of nuclear factor kappa B (NF-κB), signal transducer and activator of transcription (STATs) and nuclear factor of activated T-cells (NFAT) in mammalian immune cell lines provided evidence for heterogeneous temporal encoding of inflammatory signals. In particular, the absolute quantification of single-cell responses over time via fluorescent correlation spectroscopy (FCS) showed that NF-κB p65 activation in response to tumour necrosis factor α (TNFα) was differentially encoded in variable amplitude of nuclear translocation between immune and non-immune cells. The absolute number of activated molecules was dictated in part by the cell size, suggesting a morphology-dependent regulatory mechanism. The developed platform will enable further absolute quantitative analyses of the dynamic interactions between signalling networks, in and between individual cells, allowing better integration with mathematical models of signalling networks.


Assuntos
Técnicas de Transferência de Genes , Sistema Imunitário/citologia , Sistema Imunitário/metabolismo , Lentivirus/genética , Imagem com Lapso de Tempo/métodos , Animais , Linhagem Celular , Células HEK293 , Humanos , Fenômenos do Sistema Imunitário/genética , Células Jurkat , Camundongos , Microscopia Confocal , Modelos Imunológicos , Fatores de Transcrição NFATC/genética , Células RAW 264.7 , Fatores de Transcrição STAT/genética , Transdução de Sinais/genética , Transdução de Sinais/imunologia , Análise de Célula Única/métodos , Fator de Transcrição RelA/genética
4.
Int J Med Inform ; 46(2): 119-27, 1997 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9315501

RESUMO

This paper describes the application of rough sets theory the problem of the deciding on necessity of further tests and the final decisions about progressive encephalopathy in a child. The final decisions requires a series of invasive tests. Hence it is essential to carry out an appropriate preliminary classification. The process of the preliminary classification of patients with the use of the rough sets theory as to reduce unnecessary tests is the topic of this paper.


Assuntos
Encefalopatias/diagnóstico , Diagnóstico por Computador , Modelos Neurológicos , Adolescente , Biópsia , Encefalopatias/metabolismo , Criança , Pré-Escolar , Técnicas de Apoio para a Decisão , Feminino , Humanos , Lactente , Ácido Láctico/sangue , Ácido Láctico/líquido cefalorraquidiano , Masculino , Músculo Esquelético/patologia , Valor Preditivo dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...